ProMIS Neurosciences Inc. reported second quarter 2026 financial results and announced positive interim safety and biomarker data from its Phase 1b PRECISE-AD trial of PMN310 in early Alzheimer's disease. The company recorded a net loss of $11.7 million, or $1.28 per share, compared to a loss of $10.1 million, or $7.26 per share, in the prior year period. Cash and short-term investments totaled $53.4 million as of June 30, 2026, providing operational runway through 2027. The interim analysis showed zero cases of amyloid-related imaging abnormalities-edema (ARIA-E) across all participants and no treatment-related serious adverse events. Biomarker analyses indicated early declines in plasma pTau217 and CSF MTBR-tau243. ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases.

ProMIS Neurosciences Inc. reported positive blinded six-month interim safety and biomarker data for PMN310 in its Phase 1b PRECISE-AD trial for early Alzheimer’s disease. The analysis of 136 patients showed no cases of amyloid-related imaging abnormalities-edema (ARIA-E) across all genotypes, including APOE4 homozygotes, and a total ARIA incidence of 4.4%. Early biomarker trends indicated target engagement, with 68.5% of patients showing declines in plasma pTau217 and 62.5% showing declines in CSF MTBR-tau243. Topline 12-month results are expected in the first quarter of 2027. ProMIS Neurosciences Inc. is a clinical-stage biotechnology company developing therapeutic antibodies and vaccines for neurodegenerative diseases.